Navigation Links
Study Shows ResMed's New CPAP Device Increases Patient Compliance
Date:9/16/2010

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ResMed (NYSE: RMD), a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment today announced the results of a clinical study confirming that patients' compliance with sleep therapy increases when using ResMed's new CPAP device.

(Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

The clinical study of 50 patients suffering from sleep apnoea showed an improvement of 30 minutes in average daily usage, from a mean of 6 hours 35 minutes on the patient's usual CPAP device, to 7 hours 5 minutes, when using the new S9 Series.

Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep disorders. Obstructive sleep apnoea (OSA) is the most common type of sleep apnoea and is marked by the collapse or obstruction of the airway during sleep. The most effective treatment is Continuous Positive Airway Pressure (CPAP) therapy. In this non-invasive treatment, air is pressurised by a small device and delivered to the airway of the patient through a mask that fits on/over the nose, or nose and mouth. The pressurised air keeps the upper airway open and helps the person to get a restful night without interruptions caused by apnoeas.

A patient's ability to comply with sleep therapy, however, is affected by potential negative side effects, such as noise from the device, nasal dryness/congestion and breathing discomfort. To combat these side effects and increase patients' ability to adhere to the sleep therapy, ResMed has developed new improved features for its S9 Series including reduced noise, improved humidification system, and a more comfortable breathing system.

After testing ResMed's new sleep apnoea therapy platform, patients rate the S9 Series as significantly better than their current device in comfort of breathing, dryness of nose and mouth, rainout, and noise. In terms of overall preference, 78% preferred the S9 Series, over their current device.

"For the first time with our new ClimateControl™ system, air is delivered quietly and comfortably at the precise temperature and humidity that the sleeping patient, provider, and physician have set.  S9 Series provides a significant, patient-perceptible difference in comfort; a true leap-forward for sleep apnoea therapy," said Michael Farrell, SVP of the Global Sleep Business Unit at ResMed.

Studies conducted by researchers at Harvard Medical School show that a lack of sleep negatively affects perception and judgment. In the workplace sleep deprivation can result in reduced efficiency and productivity, errors, and accidents. Studies from the Clinical Sciences Research Institute at the University of Warwick suggest that between 6-8 hours of sleep is the optimal range.

"We are extremely pleased to see patient tests confirm that the S9 Series increases patient's compliance and quality of life, making the device a true revolution in positive airway pressure therapy," added Frank Klein, VP, European Sleep Business Unit at ResMed.

About the study

The ResMed S9 Compliance Study was conducted as a clinical study of 50 patients at the ResMed Sleep Research Centre in Sydney, Australia. The three month study comprised three stages: a retrospective study where the patients used their own device for 28 days, followed by 28 days testing S9 in a prospective study, and finally returning to the patient's own device for 28 more days in a prospective study.  

The purpose of the study was to assess whether compliance is improved by ResMed's new S9 Series, which features reduced noise, an improved humidification system and a more comfortable breathing experience. In terms of average daily usage, compliance on the S9 Series was significantly better than compliance on the patient's own device, both before and after trialling an S9 device.

The study is registered in the clinical trial registry ClinicalTrials.gov, Identifier: NCT01013207

About the S9 Series

The S9 Series is designed to deliver unsurpassed comfort to the patient by automatically controlling the pressure, temperature and humidity of the air that the patient breathes. The temperature as well as the humidity is controlled through input from five different sensors, including sensors close to the mask, a feature unique to the S9 Series over any of its competition. Optimal humidification is then achieved automatically. A new enhanced Easy-Breathe motor also reduces the conducted noise offering the quietest mask and machine combination available on the market.

About ResMed

ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contact ResMed:

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.  


'/>"/>
SOURCE ResMed
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):